Translating bacteriophage-derived depolymerases into antibacterial therapeutics: Challenges and prospects
Превращение деполимераз бактериофагового происхождения в антибактериальные терапевтические средства: проблемы и перспективы
2023-08-18
SCID: 54.1/esmwbpds
Discuss with AI
antibacterial therapeuticsantibiofilm agentsbacteriophage-derived depolymerasesmultidrug-resistant pathogensrecombinant depolymerases
Figures from the paper
Abstract (AI)
Predatory bacteriophages have evolved a vast array of depolymerases for bacteria capture and deprotection. These depolymerases are enzymes responsible for degrading diverse bacterial surface carbohydrates. They are exploited as antibiofilm agents and antimicrobial adjuvants while rarely inducing bacterial resistance, making them an invaluable asset in the era of antibiotic resistance. Numerous depolymerases have been investigated preclinically, with evidence indicating that depolymerases with appropriate dose regimens can safely and effectively combat different multidrug-resistant pathogens in animal infection models. Additionally, some formulation approaches have been developed for improved stability and activity of depolymerases. However, depolymerase formulation is limited to liquid dosage form and remains in its infancy, posing a significant hurdle to their clinical translation, compounded by challenges in their applicability and manufacturing. Future development must address these obstacles for clinical utility. Here, after unravelling the history, diversity, and therapeutic use of depolymerases, we summarized the preclinical efficacy and existing formulation findings of recombinant depolymerases. Finally, the challenges and perspectives of depolymerases as therapeutics for humans were assessed to provide insights for their further development.
Key Findings
1
Bacteriophage-derived depolymerases degrade diverse bacterial surface carbohydrates and can function as antibiofilm agents and antimicrobial adjuvants.
2
Clinical translation is hindered by unresolved challenges involving formulation, therapeutic applicability, and manufacturing.
3
Depolymerases rarely induce bacterial resistance, making them promising tools against antibiotic-resistant infections.
4
Formulation strategies have improved depolymerase stability and activity, but development remains largely limited to liquid dosage forms.
5
Preclinical studies indicate that appropriately dosed depolymerases can safely and effectively combat multiple multidrug-resistant pathogens in animal infection models.
Research Object
bacteriophage-derived depolymerases as antibacterial therapeutics
Research Subject
the preclinical efficacy, formulation, stability, activity, clinical translation challenges, and therapeutic prospects of recombinant depolymerases
Publication Details
Publication Date
2023-08-18
Journal
Publisher
ISSN
Cited by
89
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
References available in scid.ai9
Bacteriophage-encoded virion-associated enzymes to overcome the carbohydrate barriers during the infection process2017
Diversity and Function of Phage Encoded Depolymerases2020
A Novel Polysaccharide Depolymerase Encoded by the Phage SH-KP152226 Confers Specific Activity Against Multidrug-Resistant Klebsiella pneumoniae via Biofilm Degradation2019
Bacteriophage-Derived Depolymerases against Bacterial Biofilm2021
Phage-Borne Depolymerases Decrease Klebsiella pneumoniae Resistance to Innate Defense Mechanisms2018
Modeling the Architecture of Depolymerase-Containing Receptor Binding Proteins in Klebsiella Phages2019
The O-specific polysaccharide lyase from the phage LKA1 tailspike reduces Pseudomonas virulence2017
Phage-Derived Depolymerase as an Antibiotic Adjuvant Against Multidrug-Resistant Acinetobacter baumannii2022
The Specific Capsule Depolymerase of Phage PMK34 Sensitizes Acinetobacter baumannii to Serum Killing2022